tiprankstipranks
Advertisement
Advertisement

TVRD Stock Latest News

Tvardi: Strategic Pivot to Ulcerative Colitis and Upcoming HCC Readouts Support Unchanged $9 Price Target and Buy Rating
RatingsTvardi: Strategic Pivot to Ulcerative Colitis and Upcoming HCC Readouts Support Unchanged $9 Price Target and Buy Rating
25s ago
TVRD
Tvardi plans 2027 ulcerative colitis trial for oral STAT3 inhibitor TTI-109
PremiumThe Fly
Tvardi plans 2027 ulcerative colitis trial for oral STAT3 inhibitor TTI-109
15d ago
TVRD
Tvardi Therapeutics Targets Ulcerative Colitis With STAT3 Inhibitor
PremiumCompany Announcements
Tvardi Therapeutics Targets Ulcerative Colitis With STAT3 Inhibitor
15d ago
8K
TVRD
Tvardi Therapeutics Expands At-The-Market Equity Program
PremiumCompany Announcements
Tvardi Therapeutics Expands At-The-Market Equity Program
28d ago
8K
TVRD
Snap, AT&T, Lemonade, Tvardi, Dollar Tree Trending by Analysts
PremiumWeekend Updates
Snap, AT&T, Lemonade, Tvardi, Dollar Tree Trending by Analysts
1M ago
T
DLTR
Tvardi Therapeutics upgraded to Overweight at Piper after Phase 1 data
PremiumThe FlyTvardi Therapeutics upgraded to Overweight at Piper after Phase 1 data
1M ago
TVRD
Tvardi Therapeutics upgraded to Overweight from Neutral at Piper Sandler
Premium
The Fly
Tvardi Therapeutics upgraded to Overweight from Neutral at Piper Sandler
1M ago
TVRD
Why Is Penny Stock Tvardi Therapeutics (TVRD) Up Today?
Premium
Market News
Why Is Penny Stock Tvardi Therapeutics (TVRD) Up Today?
1M ago
TVRD
Tvardi Therapeutics upgraded to Outperform from Market Perform at Raymond James
PremiumThe Fly
Tvardi Therapeutics upgraded to Outperform from Market Perform at Raymond James
1M ago
TVRD
Tvardi Therapeutics announces positive Phase 1 results for TTI-109
PremiumThe Fly
Tvardi Therapeutics announces positive Phase 1 results for TTI-109
1M ago
TVRD
Tvardi Therapeutics Reports Phase 1 Data for TTI-109
PremiumCompany Announcements
Tvardi Therapeutics Reports Phase 1 Data for TTI-109
1M ago
8K
TVRD
Tvardi, Biogen, FuelCell, Magnite, Canadian Tire Trending
PremiumWeekend Updates
Tvardi, Biogen, FuelCell, Magnite, Canadian Tire Trending
2M ago
BIIB
FCEL
Tvardi Therapeutics Shareholders Approve Directors and Governance Measures
PremiumCompany AnnouncementsTvardi Therapeutics Shareholders Approve Directors and Governance Measures
2M ago
8K
TVRD
Tvardi Therapeutics initiated with a Buy at H.C. Wainwright
Premium
The Fly
Tvardi Therapeutics initiated with a Buy at H.C. Wainwright
2M ago
TVRD
5 Healthcare Stocks Set to Join the Russell 3000
Premium
Market News
5 Healthcare Stocks Set to Join the Russell 3000
3M ago
QSI
AGEN
Tvardi Therapeutics reports Q1 EPS (73c), consensus (72c)
PremiumThe Fly
Tvardi Therapeutics reports Q1 EPS (73c), consensus (72c)
3M ago
TVRD
Tvardi Therapeutics files $200M mixed securities shelf
PremiumThe Fly
Tvardi Therapeutics files $200M mixed securities shelf
3M ago
TVRD
Tvardi Therapeutics downgraded to Underweight from Equal Weight at Barclays
PremiumThe Fly
Tvardi Therapeutics downgraded to Underweight from Equal Weight at Barclays
4M ago
TVRD
Buy Rating on Tvardi: Differentiated STAT3 Platform, Upcoming TTI-109/TTI-101 Catalysts, and Attractive Risk‑Reward Through 2026
PremiumRatings
Buy Rating on Tvardi: Differentiated STAT3 Platform, Upcoming TTI-109/TTI-101 Catalysts, and Attractive Risk‑Reward Through 2026
4M ago
TVRD
Tvardi Therapeutics Warns Animal Welfare Rules Could Raise Costs and Delay Drug Development
PremiumCompany AnnouncementsTvardi Therapeutics Warns Animal Welfare Rules Could Raise Costs and Delay Drug Development
4M ago
TVRD
Tvardi Therapeutics price target lowered to $3 from $4 at Piper Sandler
Premium
The Fly
Tvardi Therapeutics price target lowered to $3 from $4 at Piper Sandler
5M ago
TVRD
Tvardi Therapeutics price target lowered to $4 from $5 at Barclays
Premium
The Fly
Tvardi Therapeutics price target lowered to $4 from $5 at Barclays
5M ago
TVRD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >